Table 3 The lung function decline and progression as assessed by decline of A) FVC %, predicted, and B) DL_CO %, predicted, in groups of patients on pirfenidone and no-antifibrotic treatments

6 mo

Decline FVC %, predicted

1.0 ± 8.2*

− 2.1 ± 10.2

0.028

% patients with decline ≥5%/decline < 5%

17.3%/82.7%

35.0%/65.0%

0.004

% patients with decline ≥10%/decline < 10%

5.3%/94.7%

18.3%/81.7%

0.558

12 mo

Decline FVC %, predicted

0.2 ± 9.2

− 4.9 ± 10.5*

< 0.001

% patients with decline ≥5%/decline < 5%

25.2%/74.8%

44.4%/55.6%

0.003

% patients with decline ≥10%/decline < 10%

10.7%/89.3%

25.0%/75.0%

0.064

18 mo

Decline FVC %, predicted

−1.1 ± 10.4

− 6.0 ± 11.1*

0.016

% patients with decline ≥5%/decline < 5%

35.5%/64.5%

51.5%/48.5%

0.116

% patients with decline ≥10%/decline < 10%

16.6%/83.4%

24.2%/75.8%

0.818

24 mo

Decline FVC %, predicted

−0.9 ± 10.7

−6.7 ± 11.3*

0.003

% patients with decline ≥5%/decline < 5%

34.8%/65.2%

50.0%/50.0%

0.102

% patients with decline ≥10%/decline < 10%

17.0%/83.0%

31.0%/69.0%

0.420

6 mo

Decline DL_CO (%), predicted

−1.6 ± 10.0*

− 4.6 ± 10.3*

0.036

% patients with decline ≥10%/decline < 10%

15.4%/84.6%

18.6%/81.4%

0.558

% patients with decline ≥15%/decline < 15%

6.1%/93.9%

8.5%/91.5%

0.559

12 mo

Decline DL_CO (%), predicted

−2.4 ± 11.0*

− 6.0 ± 11.6*

0.021

% patients with decline ≥10%/decline < 10%

19.7%/80.3%

30.8%/69.2%

0.064

% patients with decline ≥15%/decline < 15%

11.3%/88.7%

18.5%/81.5%

0.143

18 mo

Decline DL_CO (%), predicted

−3.6 ± 12.1*

− 6.1 ± 12.6*

0.294

% patients with decline ≥10%/decline < 10%

22.4%/77.6%

25.0%/75.0%

0.818

% patients with decline ≥15%/decline < 15%

11.5%/88.5%

12.5%/87.5%

0.772

24 mo

Decline DL_CO (%), predicted

−4.7 ± 11.8*

− 8.5 ± 10.1*

0.072

% patients with decline ≥10%/decline < 10%

26.3%/73.7%

33.3%/66.7%

0.420

% patients with decline ≥15%/decline < 15%

14.3%/85.7%

25.6%/74.4%

0.142